NCIMI Voices

NCIMI Voices

Expert insights on the future of AI and healthcare. Welcome to a new series by NCIMI – the National Consortium for Intelligent Medical Imaging. Join Claire Bloomfield, CEO of NCIMI, and a range of experts from across the UK to explore the opportunities for artificial intelligence in healthcare. We work with innovating companies from the medi-tech industry, leading consultants and clinicians at NHS trusts across the UK, plus charities and patient groups to explore what AI could to do to improve both diagnosis and treatment of a range of conditions. Thank you to our funders, Innovate UK.

Episodes

  1. 05/17/2021

    NCIMI Voices Episode 6: AI and lung health – Detecting lung nodules and beyond

    On this episode of NCIMI Voices, we celebrate advances in algorithms for detecting early stage lung cancer. Claire Bloomfield speaks with by Prof Fergus Gleeson, NCIMI's Chief Medical Officer and chief investigator for the DART research programme. They are joined by Optellum's CEO Václav Potěšil who talks about the company's recent FDA clearance in the US for Virtual Nodule Clinic to detect potentially cancerous nodules (small lesions) on lungs. We cover: -  Fergus on the DART programme for lung health and how it works with Optellum as a partner. -  Václav explains how their AI algorithm supports workflow and accurate decision making in a clinical setting. -  Václav explaining why FDA clearance for Optellum’s Virtual Nodule Clinic is “The biggest milestone in the history of our company”. -  How has Covid 19 impacted diagnosis and treatment of lung cancer? How could AI help support workflow? -  Where are we heading next? Optellum’s vision for CE marking and wider lung health to enable patients to be diagnosed and doctors to make optimum decisions for treatment to radically improve patient outcomes. About DART About Optellum Optellum is a lung health company, providing artificial intelligence software for clinicians to make the best decisions for early diagnosis and optimal treatment for every patient. Optellum was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, and cured. The company’s vision is to redefine early intervention of diseases like lung cancer, by enabling every clinician, in every hospital, to make the right decisions and give their patients the best chance to fight back. Optellum’s Virtual Nodule Clinic is the first clinical decision support software for personalised early diagnosis and treatment of lung cancer, based on artificial intelligence (AI) and machine learning applied to the world’s largest clinical dataset. https://optellum.com https://twitter.com/Optellum https://www.linkedin.com/company/optellum Thanks to our funders, Innovate UK. Check out our BRAND NEW WEBSITE! https://ncimi.co.uk/ Follow Claire on LinkedIn Follow us on Twitter: @NCIMImaging

    39 min
  2. 06/15/2020

    NCIMI Voices Episode 3: Data for Discovery

    Using healthcare data to improve diagnosis and treatment of patients with a huge range of medical conditions is right at the heart of NCIMI’s mission. But what are the ethical and legal implications of using anonymous patient data to develop medical technology? NCIMI has been working closely with Future Care Capital (FCC) and Anthony Collins Solicitors LLP to undertake an analysis of the legal provisions and issues impacting research and commercial usage of healthcare data. On this episode of NCIMI Voices, Claire talks to Annemarie Naylor, Director of Policy and Strategy at FCC, who was instrumental in developing the report - Research and Commercial Use of Healthcare Data: a review of the legal issues surrounding the potential ownership and exploitation of health data. And to bring a patient perspective, we have Neil McClements who is CEO of the charity Haemochromatosis UK. Together, they discuss the opportunities and challenges of working with patient data for the purposes of discovery. About Haemochromatosis UK Haemochromatosis is a genetic condition where a person absorbs too much iron from the diet, creating “iron overload”.  Neil talks about how use of patient data is as important as donating blood – something his service users know a lot about, since regular blood donation is an effective treatment for people living with Haemochromatosis. Impact of Iron Overload – report launched at Parliament in late 2018 : https://www.haemochromatosis.org.uk/the-impact-of-iron-overload State of the Nation – our most recent report delivered to the All Party Parliamentary Group on GH : https://www.haemochromatosis.org.uk/state-of-the-nation-2020 About NCIMI: https://www.medsci.ox.ac.uk/research/networks/national-consortium-of-intelligent-medical-imaging Twitter: https://twitter.com/ncimimaging LinkedIn page: https://www.linkedin.com/company/42963713/admin/ NCIMI’s approach to ethics and data: https://www.medsci.ox.ac.uk/research/networks/national-consortium-of-intelligent-medical-imaging/ncimi-and-ethics Blog by Claire and Annemarie  – https://futurecarecapital.org.uk/latest/use-of-healthcare-data-in-uncertain-times Full report here: https://futurecarecapital.org.uk/research/research-and-commercial-use-of-healthcare-data. (Also attached) About FCC Future Care Capital (FCC) is an independent charity shaping the future of health and social care. They drive innovation and improvement through leading edge research and policy insights, and by bringing together policy makers and practitioners. https://futurecarecapital.org.uk/ https://twitter.com/FCC_UK/

    36 min

About

Expert insights on the future of AI and healthcare. Welcome to a new series by NCIMI – the National Consortium for Intelligent Medical Imaging. Join Claire Bloomfield, CEO of NCIMI, and a range of experts from across the UK to explore the opportunities for artificial intelligence in healthcare. We work with innovating companies from the medi-tech industry, leading consultants and clinicians at NHS trusts across the UK, plus charities and patient groups to explore what AI could to do to improve both diagnosis and treatment of a range of conditions. Thank you to our funders, Innovate UK.